Change of Name

Recorded: 2013-03-21 Received: 2013-03-21 Pages: 4

Assignor

CHIMIGEN INC.

Executed: 2011-11-16

Assignee

LABOPHARM INC.

102-6111 AV. ROYALMOUNT, MONTREAL (QUEBEC), CAX, H4P2T4, CANADA

Covered Properties (13)

Modulation of Factor Xa Inhibitor-Mediated Blood Loss by Partial and Transient Administration of Antidote

Application: 61/734,269 →

Solid Formulations of Liquid Biologically Active Agents

Application: 13/552,993 →

Misuse Preventative, Controlled Release Formulation

Application: 12/336,495 →

Bilayer Composition for the Sustained Release of Acetaminophen and Tramadol

Application: 12/252,117 →

Process for the Preparation of Amphiphilic Poly(N-Vinyl-2-Pyrrolidone) Block Copolymers

Application: 12/211,551 →

Water-Soluble Stabilized Self-Assembled Polyelectrolytes

Application: 11/558,543 →

Solid formulations of liquid biologically active agents

Application: 11/286,301 →

Controlled-release compositions

Application: 11/111,996 →

Sustained-Release Tramadol Formulations with 24-Hour Efficacy

Application: 11/112,008 →

Process for the Preparation of Amphiphilic Poly (N-Vinyl-2-Pyrrolidone) Block Copolymers

Application: 10/727,083 →

Ph-Sensitive Block Copolymers for Pharmaceutical Compositions

Application: 10/607,446 →

Unimolecular Polymeric Micelles with an Ionizable Inner Core

Application: 09/878,115 →

Water-Soluble Stabilized Self-Assembled Polyelectrolytes

Application: 09/877,999 →